Nanomedicine: A New Frontier in Alzheimer's Disease Drug Targeting

Overview

Journal Cent Nerv Syst Agents Med Chem

Publisher Bentham Science Publishers

Specialties Chemistry
Neurology
Pharmacology

Date 2024 Mar 29

PMID 38551038

Authors

Kalyani Pathak

Mohammad Zaki Ahmad

Riya Saikia

Manash Pratim Pathak

Jon Jyoti Sahariah

Parimita Kalita

Aparoop Das

Md Ariful Islam

Pallab Pramanik

Dubom Tayeng

Basel A Abdel-Wahab

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is a prevalent neurodegenerative disorder affecting elderly individuals, characterized by progressive cognitive decline leading to dementia. This review examines the challenges posed by anatomical and biochemical barriers such as the blood-brain barrier (BBB), blood-cerebrospinal fluid barrier (BCSFB), and p-glycoproteins in delivering effective therapeutic agents to the central nervous system (CNS) for AD treatment. This article outlines the fundamental role of acetylcholinesterase inhibitors (AChEIs) and NMDA(N-Methyl-D-Aspartate) receptor antagonists in conventional AD therapy and highlights their limitations in terms of brain-specific delivery. It delves into the intricacies of BBB and pglycoprotein- mediated efflux mechanisms that impede drug transport to the CNS. The review further discusses cutting-edge nanomedicine-based strategies, detailing their composition and mechanisms that enable effective bypassing of BBB and enhancing drug accumulation in brain tissues. Conventional therapies, namely AChEIs and NMDA receptor antagonists, have shown limited efficacy and are hindered by suboptimal brain penetration. The advent of nanotechnology-driven therapeutic delivery systems offers promising strategies to enhance CNS targeting and bioavailability, thereby addressing the shortcomings of conventional treatments. Various nanomedicines, encompassing polymeric and metallic nanoparticles (MNPs), solid lipid nanoparticles (SLNs), liposomes, micelles, dendrimers, nanoemulsions, and carbon nanotubes, have been investigated for their potential in delivering anti-AD agents like AChEIs, polyphenols, curcumin, and resveratrol. These nanocarriers exhibit the ability to traverse the BBB and deliver therapeutic payloads to the brain, thereby holding immense potential for effective AD treatment and early diagnostic approaches. Notably, nanocarriers loaded with AChEIs have shown promising results in preclinical studies, exhibiting improved therapeutic efficacy and sustained release profiles. This review underscores the urgency of innovative drug delivery approaches to overcome barriers in AD therapy. Nanomedicine-based solutions offer a promising avenue for achieving effective CNS targeting, enabling enhanced bioavailability and sustained therapeutic effects. As ongoing research continues to elucidate the complexities of CNS drug delivery, these advancements hold great potential for revolutionizing AD treatment and diagnosis.

References

Caselli R, Reiman E . Characterizing the preclinical stages of Alzheimer's disease and the prospect of presymptomatic intervention. J Alzheimers Dis. 2012; 33 Suppl 1:S405-16. PMC: 3628721. DOI: 10.3233/JAD-2012-129026. View

Citron M, Oltersdorf T, Haass C, McConlogue L, Hung A, Seubert P . Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature. 1992; 360(6405):672-4. DOI: 10.1038/360672a0. View

Abbas M . Potential Role of Nanoparticles in Treating the Accumulation of Amyloid-Beta Peptide in Alzheimer's Patients. Polymers (Basel). 2021; 13(7). PMC: 8036916. DOI: 10.3390/polym13071051. View

Ferri C, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M . Global prevalence of dementia: a Delphi consensus study. Lancet. 2005; 366(9503):2112-7. PMC: 2850264. DOI: 10.1016/S0140-6736(05)67889-0. View

Barnes D, Yaffe K . The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011; 10(9):819-28. PMC: 3647614. DOI: 10.1016/S1474-4422(11)70072-2. View

Grassi D, Ferri L, Cheli P, Di Giosia P, Ferri C . Cognitive decline as a consequence of essential hypertension. Curr Pharm Des. 2011; 17(28):3032-8. DOI: 10.2174/138161211798157685. View

Abbatecola A, Olivieri F, Corsonello A, Antonicelli R, Corica F, Lattanzio F . Genome-wide association studies: is there a genotype for cognitive decline in older persons with type 2 diabetes?. Curr Pharm Des. 2011; 17(4):347-56. DOI: 10.2174/138161211795164239. View

Teixeira M, Lopes C, Amaral M, Costa P . Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases. Eur J Pharm Biopharm. 2020; 149:192-217. DOI: 10.1016/j.ejpb.2020.01.005. View

Salomone S, Caraci F, Leggio G, Fedotova J, Drago F . New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol. 2011; 73(4):504-17. PMC: 3376428. DOI: 10.1111/j.1365-2125.2011.04134.x. View

10.

Patocka J, Jun D, Kuca K . Possible role of hydroxylated metabolites of tacrine in drug toxicity and therapy of Alzheimer's disease. Curr Drug Metab. 2008; 9(4):332-5. DOI: 10.2174/138920008784220619. View

11.

Bleich S, Romer K, Wiltfang J, Kornhuber J . Glutamate and the glutamate receptor system: a target for drug action. Int J Geriatr Psychiatry. 2003; 18(Suppl 1):S33-40. DOI: 10.1002/gps.933. View

12.

Danysz W, Parsons C . The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry. 2003; 18(Suppl 1):S23-32. DOI: 10.1002/gps.938. View

13.

Silva S, Marto J, Goncalves L, Almeida A, Vale N . Formulation, Characterization and Evaluation against SH-SY5Y Cells of New Tacrine and Tacrine-MAP Loaded with Lipid Nanoparticles. Nanomaterials (Basel). 2020; 10(10). PMC: 7589787. DOI: 10.3390/nano10102089. View

14.

Whitehouse P, Price D, Struble R, CLARK A, Coyle J, Delon M . Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. 1982; 215(4537):1237-9. DOI: 10.1126/science.7058341. View

15.

Soreq H, Seidman S . Acetylcholinesterase--new roles for an old actor. Nat Rev Neurosci. 2001; 2(4):294-302. DOI: 10.1038/35067589. View

16.

Pera M, Martinez-Otero A, Colombo L, Salmona M, Ruiz-Molina D, Badia A . Acetylcholinesterase as an amyloid enhancing factor in PrP82-146 aggregation process. Mol Cell Neurosci. 2008; 40(2):217-24. DOI: 10.1016/j.mcn.2008.10.008. View

17.

De Ferrari G, Canales M, Shin I, Weiner L, Silman I, Inestrosa N . A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. Biochemistry. 2001; 40(35):10447-57. DOI: 10.1021/bi0101392. View

18.

Inestrosa N, Alvarez A, Perez C, Moreno R, Vicente M, Linker C . Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron. 1996; 16(4):881-91. DOI: 10.1016/s0896-6273(00)80108-7. View

19.

Castro A, Martinez A . Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease. Mini Rev Med Chem. 2002; 1(3):267-72. DOI: 10.2174/1389557013406864. View

20.

Giacobini E . Cholinesterases: new roles in brain function and in Alzheimer's disease. Neurochem Res. 2003; 28(3-4):515-22. DOI: 10.1023/a:1022869222652. View